| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effect of dutasteride on the risk of prostate cancer.
|
N Engl J Med
|
2010
|
12.78
|
|
2
|
Benefits and harms of CT screening for lung cancer: a systematic review.
|
JAMA
|
2012
|
8.71
|
|
3
|
Are racial and ethnic minorities less willing to participate in health research?
|
PLoS Med
|
2005
|
7.88
|
|
4
|
Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening.
|
CA Cancer J Clin
|
2010
|
4.76
|
|
5
|
Survival of blacks and whites after a cancer diagnosis.
|
JAMA
|
2002
|
4.27
|
|
6
|
Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening.
|
CA Cancer J Clin
|
2009
|
3.25
|
|
7
|
Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.
|
Breast Cancer Res Treat
|
2002
|
3.19
|
|
8
|
American Cancer Society lung cancer screening guidelines.
|
CA Cancer J Clin
|
2013
|
3.16
|
|
9
|
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
|
Breast Cancer Res Treat
|
2008
|
2.97
|
|
10
|
Cancer screening in the United States, 2011: A review of current American Cancer Society guidelines and issues in cancer screening.
|
CA Cancer J Clin
|
2011
|
2.76
|
|
11
|
American society of clinical oncology policy statement: disparities in cancer care.
|
J Clin Oncol
|
2009
|
2.12
|
|
12
|
Low-dose spiral CT screening and evaluation of the solitary pulmonary nodule.
|
Oncology (Williston Park)
|
2014
|
2.06
|
|
13
|
Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening.
|
CA Cancer J Clin
|
2015
|
1.97
|
|
14
|
Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening.
|
CA Cancer J Clin
|
2014
|
1.95
|
|
15
|
The worldwide epidemiology of prostate cancer: perspectives from autopsy studies.
|
Can J Urol
|
2008
|
1.93
|
|
16
|
Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening.
|
CA Cancer J Clin
|
2013
|
1.75
|
|
17
|
Palliative care and the quality of life.
|
J Clin Oncol
|
2011
|
1.75
|
|
18
|
The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
|
J Urol
|
2010
|
1.73
|
|
19
|
Disaggregating the effects of race and poverty on breast cancer outcomes.
|
J Natl Cancer Inst
|
2002
|
1.44
|
|
20
|
High prevalence of triple-negative tumors in an urban cancer center.
|
Cancer
|
2008
|
1.43
|
|
21
|
Effects of untreated syphilis in the negro male, 1932 to 1972: a closure comes to the Tuskegee study, 2004.
|
Urology
|
2005
|
1.42
|
|
22
|
Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States.
|
Cancer
|
2010
|
1.38
|
|
23
|
Effects of an outreach and internal navigation program on breast cancer diagnosis in an urban cancer center with a large African-American population.
|
Cancer
|
2008
|
1.36
|
|
24
|
Age and grade trends in prostate cancer (1974-2003): a Surveillance, Epidemiology, and End Results Registry analysis.
|
Am J Clin Oncol
|
2008
|
1.28
|
|
25
|
Extensive inguinal lymphadenectomy improves overall 5-year survival in penile cancer patients: results from the Surveillance, Epidemiology, and End Results program.
|
Cancer
|
2010
|
1.28
|
|
26
|
Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
1.14
|
|
27
|
Racial disparities in colorectal cancer.
|
Curr Probl Cancer
|
2007
|
1.11
|
|
28
|
From the guest editors: introduction for the impact of health care reform on cancer patients.
|
Cancer J
|
2010
|
1.08
|
|
29
|
Colorectal carcinoma in black and white race.
|
Cancer Metastasis Rev
|
2003
|
1.07
|
|
30
|
Prostate cancer: current evidence weighs against population screening.
|
CA Cancer J Clin
|
2009
|
1.05
|
|
31
|
Prostate cancer in black and white Americans.
|
Cancer Metastasis Rev
|
2003
|
1.05
|
|
32
|
Myeloma and race: a review of the literature.
|
Cancer Metastasis Rev
|
2003
|
1.00
|
|
33
|
The globalization of tobacco use: 21 challenges for the 21st century.
|
CA Cancer J Clin
|
2010
|
1.00
|
|
34
|
Disparities in medical care among commercially insured patients with newly diagnosed breast cancer: opportunities for intervention.
|
Cancer
|
2010
|
0.99
|
|
35
|
Introducing the 2010 American Cancer Society prostate cancer screening guideline.
|
CA Cancer J Clin
|
2010
|
0.99
|
|
36
|
Risk-based mammography screening: an effort to maximize the benefits and minimize the harms.
|
Ann Intern Med
|
2012
|
0.98
|
|
37
|
Is race really a negative prognostic factor for cancer?
|
J Natl Cancer Inst
|
2009
|
0.97
|
|
38
|
The study of accrual to clinical trials: can we learn from studying who enters our studies?
|
J Clin Oncol
|
2004
|
0.97
|
|
39
|
Racial disparities in lung cancer.
|
Curr Probl Cancer
|
2007
|
0.96
|
|
40
|
Examining racial differences in diffuse large B-cell lymphoma presentation and survival.
|
Leuk Lymphoma
|
2013
|
0.95
|
|
41
|
NIH consensus development statement on hydroxyurea treatment for sickle cell disease.
|
NIH Consens State Sci Statements
|
2008
|
0.95
|
|
42
|
A black-white comparison of the quality of stage-specific colon cancer treatment.
|
Cancer
|
2010
|
0.93
|
|
43
|
Characteristics and treatment modalities for African American women diagnosed with stage III breast cancer.
|
Cancer
|
2009
|
0.90
|
|
44
|
Avoidable cancer deaths globally.
|
CA Cancer J Clin
|
2011
|
0.90
|
|
45
|
Taking action to ease suffering: advancing cancer pain control as a health care priority.
|
CA Cancer J Clin
|
2009
|
0.89
|
|
46
|
Some perspective on black-white cancer statistics.
|
CA Cancer J Clin
|
2002
|
0.89
|
|
47
|
Obesity-driven inflammation and cancer risk: role of myeloid derived suppressor cells and alternately activated macrophages.
|
Am J Cancer Res
|
2013
|
0.89
|
|
48
|
Racial differences in the incidence and outcomes for patients with hematological malignancies.
|
Curr Probl Cancer
|
2007
|
0.88
|
|
49
|
Informed consent for prostate-specific antigen-based screening.
|
Urology
|
2003
|
0.84
|
|
50
|
A research agenda for radiation oncology: results of the radiation oncology institute's comprehensive research needs assessment.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.84
|
|
51
|
Health care policy and cancer survivorship.
|
Cancer
|
2013
|
0.82
|
|
52
|
Lung cancer and race: equal treatment yields equal outcome among equal patients, but there is no equal treatment.
|
J Clin Oncol
|
2005
|
0.82
|
|
53
|
CDC Grand Rounds: the future of cancer screening.
|
MMWR Morb Mortal Wkly Rep
|
2015
|
0.82
|
|
54
|
Prostate cancer screening; is this a teachable moment?
|
J Natl Cancer Inst
|
2009
|
0.81
|
|
55
|
Peak window of suicides occurs within the first month of diagnosis: implications for clinical oncology.
|
Psychooncology
|
2011
|
0.81
|
|
56
|
The National Breast and Cervical Cancer Early Detection Program: toward a system of cancer screening in the United States.
|
Cancer
|
2014
|
0.80
|
|
57
|
The potential for prostate cancer chemoprevention.
|
Rev Urol
|
2002
|
0.77
|
|
58
|
Phase III prostate cancer chemoprevention trials.
|
Recent Results Cancer Res
|
2014
|
0.75
|
|
59
|
Oophorectomy in carriers of BRCA mutations.
|
N Engl J Med
|
2002
|
0.75
|
|
60
|
The argument for breast cancer screening.
|
Clin Adv Hematol Oncol
|
2014
|
0.75
|
|
61
|
New ACS chief medical officer. Interview by Carrie Printz.
|
Cancer
|
2008
|
0.75
|
|
62
|
Chemoprevention in prostate cancer.
|
Curr Probl Cancer
|
2004
|
0.75
|
|
63
|
Curbing tobacco's toll starts with the professionals: World No Tobacco Day.
|
Lancet
|
2005
|
0.75
|
|
64
|
A brief history of the American Cancer Society Extramural Research Program.
|
CA Cancer J Clin
|
2012
|
0.75
|
|
65
|
Reviewer acknowledgment 2015.
|
CA Cancer J Clin
|
2015
|
0.75
|
|
66
|
Information over exaggeration.
|
US News World Rep
|
2009
|
0.75
|